ISSN 3105-6741(Print)
ISSN 3105-675X(Online)
版权信息 · Copyright

     加入编委 / 副主编 / 同行评议专家
ISSN 3105-6741(Print)
ISSN 3105-675X(Online)

CODEN:LYYAA3
国际标准连续出版物标识符·全球唯一标识符
分配机构:美国化学文摘社(CAS)
DOI前缀:
https://doi.org/10.66106/lyyaa3
国图集团 CIBTC
进口备案刊号:G015Z125

索引 检索 存档(Global Indexing)
本刊入选以下全球权威数据库,致力于研究成果的全球化无障碍传播。

CNKI(中国知网,申请中)
CNKI Open(中国知网·开放平台,申请中)
Wanfang Data(万方数据,中国,更新中)
CQVIP(维普期刊网,中国)
CQVIP(中文期刊服务平台,中国)
RCCSE(中国学术期刊目录,武汉大学)
CJWK(长江文库,中国)
BOOKAN(博看,中国)
591adb(中邮阅读·万章期刊,中国)
Baidu Scholar(百度学术,中国)
Baidu Baike(百度百科,中国)
ICI(哥白尼期刊数据库,波兰)
EuroPub(欧洲学术出版数据库,英国)
MDPI scilit(科学与学术数据库,瑞士)
Crossref(交叉引用,美国)
Semantic Scholar(语义学术,美国)
OpenAlex(全球开源学术平台,加拿大)
ACADEMIA.EDU(学术界,美国)
OUCI(开放乌克兰科学,乌克兰)
WorldCat(世界编目数据库,美国)
Scite(智能引文分析数据库,美国)
The Lens(透镜学术,澳大利亚)
OpenAIRE(开放学术发现门户,欧洲)
Google Scholar(谷歌学术,美国)
DOI(数字对象唯一标识符,英国)
Portico(数字存储库,美国)
J-Gate(开放获取期刊门户,印度)
ResearchGate(研究之门,德国)
Research Commons(科睿唯安,美国)
Socolar(开放获取资源检索,中国,更新中)
Sci Online(科学在线,中国澳门)
OALib(开放存取资源图书馆,美国)
EZB(电子期刊图书馆,德国,申请中)
Road(开放科学学术资源,法国)
ISI(国际科学索引平台,阿联酋迪拜)
ASCI(亚洲科学引文索引,美国)
ESJI(欧亚科学期刊索引,哈萨克斯坦)
ResearchBib(研究者索引,日本)
SPI-Hub™(范德比尔特大学,美国)
SJIF(科学期刊影响因子,印度)
RJIF(研究期刊影响因子)
COSMOS(期刊评价指标,印度)
LivRe!(开放期刊门户,巴西)
KIND CONGRESS(阿塞拜疆)
Journament(质量评估与索引)
IP Indexing(ip索引)
Magzter(跨平台数字期刊,美国)
SlideShare(知识共享平台,美国)
SCRIBD(在线图书馆,美国)
Yahoo! Search(雅虎,美国)
Microsoft Bing(微软学术,美国)
LibKey(学术文献快捷获取工具)
R Discovery(研究者发现平台,印度)
Enterscholar(恩特学术)

规划申请
Scopus 爱思唯尔·斯高帕斯(荷兰)

SinoMed 中国生物医学文献服务系统
DOAJ 开放获取期刊目录(瑞典)
PubMed 医学文摘数据库(美国)
PubMed Central 医学全文数据(美国)
EMBASE 爱思唯尔·医学文摘(荷兰)
EBSCO 学术文献数据库(美国)
OAJ 全球OA期刊索引(中国)

CABI 国际农业与生物科学中心(英国)
ProQuest 科睿唯安(美国)
Research4Life 世界卫生组织数据库


武汉办事处
主任 库盛娟
电话 +86 027-8860 7188
邮箱 gjqk@qikan999.com
微信 qikan7188
地址 武汉市武昌东湖路181号
邮编 430077
Editing and Publishing
Macau Sino-Foreign Medical Publishing Limited(MSFMP)
Address
Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
https://lcyyyj.scionline2025.com

  往期阅览 · All Issues-> 2025年 · 2025  
临床用药研究2025年第1卷第1期第30-34页,pISSN 3105-6741、eISSN 3105-675X 发布者:Quest Press 发布日期:2026/4/16
Open Access 浏览209

 

乌头汤联合治疗膝骨关节炎有效性与安全性的 Meta 分析


陈靓靓,袁文琪,张琰琳,潘长清,何歆怡,艾珏萍,莫小英,蒋荣云,刘啸天

1.长沙医学院,湖南长沙,410219;2.湖南中医药大学,湖南长沙,410208

摘要:目的:通过Meta分析方法系统评价乌头汤联合常规疗法治疗膝骨关节炎(Kneeosteoarthritis,KOA)的有效性与安全性。方法:计算机检索PubMed、MedLine、Embase、CochraneLibrary、WebofScience、中国知网、万方医学网、维普期刊等8个数据库,收集建库至2025年12月20日发表的相关文献。纳入乌头汤联合治疗KOA的随机对照试验(Randomizedcontrolledtrial,RCT),由两名研究员独立筛选文献、提取数据,并采用改良Jadad量表评估文献质量。使用Stata18.0和ReviewManager5.4软件进行Meta分析,通过异质性检验、敏感性分析和发表偏倚评估结果的稳健性。结果:共纳入7项RCT研究,总计1487例患者(观察组750例,对照组737例)。Meta分析显示,乌头汤联合治疗在提高治愈率(OR=3.22,95%CI:2.49~4.15,P<0.001)和有效率(OR=3.72,95%CI:2.71~5.10,P<0.001)方面显著优于对照组。异质性检验提示治愈率与有效率的研究异质性较低,敏感性分析结果稳健。漏斗图与Egger检验提示治愈率分析存在发表偏倚(P=0.008),有效率分析未发现明显发表偏倚(P=0.436)。结论:乌头汤联合治疗可显著提升膝骨关节炎的治愈率和有效率,且整体安全性良好,具有较高的临床应用价值。

关健词:膝骨关节炎;乌头汤;联合治疗;有效性;安全性;Meta 分析
Meta-analysis of the efficacy and safety of Wutau decoction in the treatment of knee osteoarthritis

Liangliang Chen,Wenqi Yuan,Yanlin Zhang,Changqing Pan,Xinyi He,Jueping Ai,iaoying Mo,Rongyun Jiang,Xiaotian Liu

1.Changsha Medical University,Changsha,Hunan,410219;2. Hunan University of Chinese Medicine,Changsha,Hunan,410208

Abstract:Objective:To evaluate the efficacy and safety of Wutai decoction combined with conventional therapy in the treatment of Knee osteoarthritis(KOA)by Meta-analysis. Methods:PubMed,MedLine,Embase,Cochrane Library,Web of Science,China National Knowledge Infrastructure(CNKI),Wanfang Medical Network,and VIP journals were searched by computer. Relevant articles published before December 20,2025 were collected. A Randomized controlled trial (RCT)of Wutau decoction combined with KOA was included. Two researchers independently screened the literature,extracted the data,and evaluated the quality of the literature by the modified Jadad scale. Meta-analysis was performed using Stata 18.0 and Review Manager 5.4 software,and the robustness of the results was evaluated by heterogeneity test,sensitivity analysis and publication bias. Results: A total of 7 RCTS involving 1487 patients(750 in the observation group and 737 in the control group)wereincluded. Meta-analysis showed that the combination of Wutau decoction was significantly better than the control group in improving the cure rate (OR=3.22,95%CI: 2.49-4.15,P < 0.001)and effective rate(OR=3.72,95%CI: 2.71-5.10,P < 0.001). The heterogeneity test suggested that the heterogeneity of the cure rate and response rate was low,and the sensitivity analysis results were robust. Funnel plot and Egger test suggested that there was publication bias in the cure rate analysis (P=0.008),but no significant publication bias was found in the effective rate analysis (P=0.436). Conclusion:The combined treatment with Wutou Decoction can significantly increase the cure rate and effective rate of knee osteoarthritis,and has overall good safety,with high clinical application value.


Keywords : Knee osteoarthritis;Wutau decoction;combination therapy;efficacy;safety;meta-analysis


参考文献
[1] 刘卓,熊诗丹,陈星,等.乌头散外敷治疗寒湿闭阻型膝骨关节炎的临床研究[J].中国民族医药杂志,2023,29(03):26-27.
[2] 王玮莉,孙恒聪,黄金波,等.不同针药联合方案治疗阳虚寒凝型膝骨关节炎疗效观察[J].针灸临床杂志,2019,35(09):30-33.
[3] 万峰格,邹吉锋,李桂云.乌头汤外用熏洗对寒证膝骨关节炎局部痛阈及皮温的影响[J].现代中西医结合杂志,2021,30(07):759-762.
[4] Moher D,Shamseer L,Clarke M,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P)2015 statement[J]. Systematic Reviews,4(1):1.
[5] Jadad AR,Moore RA,Carroll D,et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary[J]. Controlled Clinical Trials,17(1),1-12.
[6] 戴越保,周章武.加味乌头汤配合玻璃酸钠关节腔注射治疗膝骨性关节炎 24 例[J].湖南中医杂志,2013,29(09):82-84.
[7] 鞠晓伟,罗宗键,吴晓光,等.乌头汤联合塞来昔布治疗风寒湿痹证膝关节骨性关节炎的临床观察[J].世界中西医结合杂志,2022,17(02):346-349+353.
[8] 黎友允,刘晨峰,姚先秀,等.乌头汤治疗膝关节骨性关节炎的效果分析[J].中国当代医药,2013,20(21):129-130.
[9] 孙有松,周爱芹,张涛.虫药五味乌头汤治疗膝骨性关节炎 395 例[J].河南中医,2011,31(10):1144.
[10] 王诗康.乌头汤结合西药治疗膝骨性关节炎的疗效观察[J].基层医学论坛,2015,19(18):2526-2527.
[11] 吴李秀,俞坤强,朱慧梅,等.筋针联合乌头汤治疗寒湿痹阻型早中期膝骨关节炎患者的临床疗效及其对血清 CTX-Ⅱ、COMP 的影响[J].中国现代医生,2021,59(22):13-16.
[12] 郑倩仪,陈伯健.经方乌头汤配合电脑中频导入穴位治疗膝骨关节炎[J].实用医学杂志,2009,25(06): 984-985.
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
版权声明
Copyright Statement
本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问: https://creativecommons.org/licenses/by/4.0/
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.

 
Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
关于 Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Joining the Editorial Board, Associate Editors, Peer Reviewers, and Editor-in-Chief
加入编委、副主编、同行评审专家及主编
Quest Press
Bridging Research to a Global Stage.
academia
© 2025-2026 Macau Sino-Foreign Medical Publishing Ltd.(MSFMP)
Address: Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Tel: +853 6881 9699 / Email: QuestPress@hotmail.com
The MSFMP publishes articles under the following open access license.
Quest Press
is a member of the following organizations.